We found a significant PFS improvement in MUC16 variant vs wild-type tumors among patients with EGFR or ALK variant NSCLC (HR, 0.32; 95% CI 0.11-0.92; P = .03). This evidence concerns the gene MUC16 and non-small cell lung carcinoma.